Singh, J.; Johar, T.; Scully, V.; Waldman, S.A.; Bashir, B.; Snook, A.E.
In-Use Stability and Device Compatibility Define Clinically Actionable Handling Limits for a GMP-Produced Attenuated Listeria monocytogenes Vaccine Expressing GUCY2C. Vaccines 2026, 14, 461.
https://doi.org/10.3390/vaccines14050461
AMA Style
Singh J, Johar T, Scully V, Waldman SA, Bashir B, Snook AE.
In-Use Stability and Device Compatibility Define Clinically Actionable Handling Limits for a GMP-Produced Attenuated Listeria monocytogenes Vaccine Expressing GUCY2C. Vaccines. 2026; 14(5):461.
https://doi.org/10.3390/vaccines14050461
Chicago/Turabian Style
Singh, Jagmohan, Taranjot Johar, Vannessa Scully, Scott A. Waldman, Babar Bashir, and Adam E. Snook.
2026. "In-Use Stability and Device Compatibility Define Clinically Actionable Handling Limits for a GMP-Produced Attenuated Listeria monocytogenes Vaccine Expressing GUCY2C" Vaccines 14, no. 5: 461.
https://doi.org/10.3390/vaccines14050461
APA Style
Singh, J., Johar, T., Scully, V., Waldman, S. A., Bashir, B., & Snook, A. E.
(2026). In-Use Stability and Device Compatibility Define Clinically Actionable Handling Limits for a GMP-Produced Attenuated Listeria monocytogenes Vaccine Expressing GUCY2C. Vaccines, 14(5), 461.
https://doi.org/10.3390/vaccines14050461
